Evidence map›Paper›PMID 29770799›Full record

ReviewActa pharmacologica Sinica2018

Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis.

Xiao-Dong Ye, Yi He, Sheng Wang, Gordon T Wong, Michael G Irwin, Zhengyuan Xia

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Advances in biomarkers for myocardial injury after non-cardiac surgery.Journal of anesthesia and translational medicine · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis.International journal of molecular sciences · 2025
    Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Xiao-Dong YeDepartment of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yi HeDepartment of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Sheng WangGuangdong Cardiovascular Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China, 510080.
Gordon T WongDepartment of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Michael G IrwinDepartment of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. zyxia@hku.hk.
Zhengyuan XiaDepartment of Anaesthesiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. zyxia@hku.hk.
Chinese University of Hong Kong · CNUniversity of Hong Kong · HKGuangdong Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myocardial infarction (AMI) is a life-threatening event. Even with timely treatment, acute ischemic myocardial injury and ensuing ischemia reperfusion injury (IRI) can still be difficult issues to tackle. Apart from radiological and other auxiliary examinations, laboratory tests of applicable cardiac biomarkers are also necessary for early diagnosis and close monitoring of this disorder. Heart-type fatty acid binding protein (H-FABP), which mainly exists inside cardiomyocytes, has recently emerged as a potentially promising biomarker for myocardial injury. In this review we discuss the sensitivity and specificity of H-FABP in the assessment of myocardial injury and IRI, especially in the early stage, and its long-term prognostic value in comparison with other commonly used cardiac biomarkers, including myoglobin (Mb), cardiac troponin I (cTnI), creatine kinase MB (CK-MB), C-reactive protein (CRP), glycogen phosphorylase isoenzyme BB (GPBB), and high-sensitivity cardiac troponin T (hs-cTnT). The potential and value of combined application of H-FABP with other biomarkers are also discussed. Finally, the prospect of H-FABP is summarized; several technical issues are discussed to facilitate wider application of H-FABP in clinical practice.

Indexed as

BiomarkersFatty Acid-Binding ProteinsHumansMyocardial InfarctionMyocardial Reperfusion InjuryBiomarkersFatty Acid-Binding Proteinsacute myocardial infarctioncardiac biomarkersheart-type fatty acid binding proteinischemia reperfusion injurypost-ischemic myocardial injury

Identifiers

PMID29770799
PMCPMC6289342
OpenAlexW2803218851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.